Ontology type: schema:ScholarlyArticle Open Access: True
2017-02-21
AUTHORSEileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu, Douglas Johnson
ABSTRACTBackgroundImmune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis are well described, but less frequent events are now emerging with larger numbers of patients treated. Herein we describe the incidence and spectrum of thrombocytopenia following immune checkpoint inhibitor therapy and two severe cases of idiopathic thrombocytopenic purpura (ITP).Case presentationsA 47-year-old female with recurrent BRAF mutant positive melanoma received combination anti-PD-1 and anti-CTLA-4. Two weeks later, she presented with mucosal bleeding, petechiae, and thrombocytopenia and was treated with standard therapy for ITP with steroids and intravenous immunoglobulin (IVIG). Her diagnosis was confirmed with bone marrow biopsy, and given the lack of treatment response, she was treated with rituximab. She began to have recovery and stabilization of her platelet count that ultimately allowed her to be retreated with PD-1 inhibition with no further thrombocytopenia. A second patient, a 45-year-old female with a BRAF wild-type melanoma, received anti-PD-1 monotherapy and became thrombocytopenic 43 days later. Three weeks of steroid treatment improved her platelet count, but thrombocytopenia recurred and required additional steroids. She later received anti-CTLA-4 monotherapy and developed severe ITP with intracranial hemorrhage. Her ITP resolved after treatment of prednisone, IVIG, and rituximab and discontinuation of checkpoint inhibition. In a retrospective chart review of 2360 patients with melanoma treated with checkpoint inhibitor therapy, <1% experienced thrombocytopenia following immune checkpoint inhibition, and of these, most had spontaneous resolution and did not require treatment.ConclusionsThrombocytopenia, especially ITP, induced by immune checkpoint inhibitors appears to be an uncommon irAE that is manageable with observation in mild cases and/or standard ITP treatment algorithms. In our series, the majority of patients had mild thrombocytopenia that resolved spontaneously or responded to standard corticosteroid regimens. However, in two severe cases, IVIG and rituximab, in addition to steroids, were required. Checkpoint inhibition was resumed successfully in the first patient but rechallenge was not tolerated by the second patient. More... »
PAGES8
http://scigraph.springernature.com/pub.10.1186/s40425-017-0210-0
DOIhttp://dx.doi.org/10.1186/s40425-017-0210-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1083870665
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/28239462
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Immunology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Immunological",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "CTLA-4 Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ipilimumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Melanoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Nivolumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Programmed Cell Death 1 Receptor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Rituximab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Skin Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Thrombocytopenia",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Cancer Biology, Vanderbilt University Medical Center, 37232, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.412807.8",
"name": [
"Medical Scientist Training Program, Vanderbilt University Medical Center, 37232, Nashville, TN, USA",
"Department of Cancer Biology, Vanderbilt University Medical Center, 37232, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Shiuan",
"givenName": "Eileen",
"id": "sg:person.010435617535.02",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010435617535.02"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.412807.8",
"name": [
"Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Beckermann",
"givenName": "Kathryn E.",
"id": "sg:person.012606013511.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012606013511.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 33612, Tampa, FL, USA",
"id": "http://www.grid.ac/institutes/grid.468198.a",
"name": [
"Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 33612, Tampa, FL, USA"
],
"type": "Organization"
},
"familyName": "Ozgun",
"givenName": "Alpaslan",
"id": "sg:person.01262131140.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262131140.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sarcoma Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.51462.34",
"name": [
"Sarcoma Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Kelly",
"givenName": "Ciara",
"id": "sg:person.01326747765.81",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326747765.81"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "McKean",
"givenName": "Meredith",
"id": "sg:person.013644530711.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013644530711.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "McQuade",
"givenName": "Jennifer",
"id": "sg:person.01053461302.50",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053461302.50"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 37232, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.412807.8",
"name": [
"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 37232, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Thompson",
"givenName": "Mary Ann",
"id": "sg:person.014045623467.97",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014045623467.97"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Roswell Park Cancer Institute, 14263, Buffalo, NY, USA",
"id": "http://www.grid.ac/institutes/grid.240614.5",
"name": [
"Roswell Park Cancer Institute, 14263, Buffalo, NY, USA"
],
"type": "Organization"
},
"familyName": "Puzanov",
"givenName": "Igor",
"id": "sg:person.0640153517.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.412807.8",
"name": [
"Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Greer",
"givenName": "John P.",
"id": "sg:person.01017773135.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017773135.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 20057, Washington, DC, USA",
"id": "http://www.grid.ac/institutes/grid.213910.8",
"name": [
"Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 20057, Washington, DC, USA"
],
"type": "Organization"
},
"familyName": "Rapisuwon",
"givenName": "Suthee",
"id": "sg:person.01155613526.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155613526.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Weill Cornell Medical College, Cornell University, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA",
"Weill Cornell Medical College, Cornell University, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Postow",
"givenName": "Michael",
"id": "sg:person.0663446543.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Davies",
"givenName": "Michael A.",
"id": "sg:person.01357706621.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357706621.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 33612, Tampa, FL, USA",
"id": "http://www.grid.ac/institutes/grid.468198.a",
"name": [
"Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 33612, Tampa, FL, USA"
],
"type": "Organization"
},
"familyName": "Eroglu",
"givenName": "Zeynep",
"id": "sg:person.01307354527.86",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307354527.86"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.412807.8",
"name": [
"Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Johnson",
"givenName": "Douglas",
"id": "sg:person.015122302157.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015122302157.06"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s12325-015-0251-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014223155",
"https://doi.org/10.1007/s12325-015-0251-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00277-016-2641-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009404882",
"https://doi.org/10.1007/s00277-016-2641-y"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-02-21",
"datePublishedReg": "2017-02-21",
"description": "BackgroundImmune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis are well described, but less frequent events are now emerging with larger numbers of patients treated. Herein we describe the incidence and spectrum of thrombocytopenia following immune checkpoint inhibitor therapy and two severe cases of idiopathic thrombocytopenic purpura (ITP).Case presentationsA 47-year-old female with recurrent BRAF mutant positive melanoma received combination anti-PD-1 and anti-CTLA-4. Two weeks later, she presented with mucosal bleeding, petechiae, and thrombocytopenia and was treated with standard therapy for ITP with steroids and intravenous immunoglobulin (IVIG). Her diagnosis was confirmed with bone marrow biopsy, and given the lack of treatment response, she was treated with rituximab. She began to have recovery and stabilization of her platelet count that ultimately allowed her to be retreated with PD-1 inhibition with no further thrombocytopenia. A second patient, a 45-year-old female with a BRAF wild-type melanoma, received anti-PD-1 monotherapy and became thrombocytopenic 43\u00a0days later. Three weeks of steroid treatment improved her platelet count, but thrombocytopenia recurred and required additional steroids. She later received anti-CTLA-4 monotherapy and developed severe ITP with intracranial hemorrhage. Her ITP resolved after treatment of prednisone, IVIG, and rituximab and discontinuation of checkpoint inhibition. In a retrospective chart review of 2360 patients with melanoma treated with checkpoint inhibitor therapy, <1% experienced thrombocytopenia following immune checkpoint inhibition, and of these, most had spontaneous resolution and did not require treatment.ConclusionsThrombocytopenia, especially ITP, induced by immune checkpoint inhibitors appears to be an uncommon irAE that is manageable with observation in mild cases and/or standard ITP treatment algorithms. In our series, the majority of patients had mild thrombocytopenia that resolved spontaneously or responded to standard corticosteroid regimens. However, in two severe cases, IVIG and rituximab, in addition to steroids, were required. Checkpoint inhibition was resumed successfully in the first patient but rechallenge was not tolerated by the second patient.",
"genre": "article",
"id": "sg:pub.10.1186/s40425-017-0210-0",
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.2683740",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.2438793",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.6442653",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1049249",
"issn": [
"2051-1426"
],
"name": "Journal for ImmunoTherapy of Cancer",
"publisher": "BMJ",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "5"
}
],
"keywords": [
"idiopathic thrombocytopenic purpura",
"checkpoint inhibitor therapy",
"immune checkpoint inhibitor therapy",
"intravenous immunoglobulin",
"inhibitor therapy",
"checkpoint inhibition",
"checkpoint inhibitors",
"second patient",
"platelet count",
"severe cases",
"anti-PD-1 monotherapy",
"severe idiopathic thrombocytopenic purpura",
"T-lymphocyte antigen-4",
"BRAF wild-type melanoma",
"BackgroundImmune checkpoint inhibitors",
"treatment of prednisone",
"immune checkpoint inhibition",
"immune checkpoint inhibitors",
"PD-1 inhibition",
"retrospective chart review",
"majority of patients",
"wild-type melanoma",
"bone marrow biopsy",
"corticosteroid regimens",
"mucosal bleeding",
"adverse events",
"standard therapy",
"steroid treatment",
"chart review",
"death-1",
"thrombocytopenic purpura",
"treatment algorithm",
"treatment of cancer",
"marrow biopsy",
"intracranial hemorrhage",
"first patient",
"antigen-4",
"additional steroids",
"mild cases",
"mild thrombocytopenia",
"treatment response",
"positive melanoma",
"thrombocytopenia",
"spontaneous resolution",
"patients",
"therapy",
"melanoma",
"steroids",
"monotherapy",
"treatment",
"frequent event",
"inhibition",
"weeks",
"inhibitors",
"females",
"count",
"ConclusionsThrombocytopenia",
"colitis",
"pneumonitis",
"rituximab",
"prednisone",
"rechallenge",
"purpura",
"bleeding",
"discontinuation",
"regimens",
"hemorrhage",
"petechiae",
"biopsy",
"irAE",
"dermatitis",
"cancer",
"incidence",
"immunoglobulin",
"diagnosis",
"Immune",
"cases",
"antibodies",
"days",
"events",
"review",
"majority",
"response",
"recovery",
"less frequent events",
"lack",
"large number",
"combination",
"frequency",
"addition",
"number",
"series",
"Herein",
"stabilization",
"observations",
"resolution",
"spectra",
"algorithm"
],
"name": "Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy",
"pagination": "8",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1083870665"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s40425-017-0210-0"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"28239462"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s40425-017-0210-0",
"https://app.dimensions.ai/details/publication/pub.1083870665"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:05",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_754.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s40425-017-0210-0"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0210-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0210-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0210-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0210-0'
This table displays all metadata directly associated to this object as RDF triples.
341 TRIPLES
21 PREDICATES
138 URIs
128 LITERALS
20 BLANK NODES